On March 27, 2021, the ” the 2021 Beijing Obstetrics and Gynecology Academic Annual Meeting ” sponsored by Beijing Branch of Chinese Medical Association and Obstetrics and Gynecology branch of Beijing Medical Association was held in Beijing. As one of the important partners and supporters of this meeting, Boyalife attended the meeting and assisted the academic annual meeting to be successfully held.
Duan Hua, vice chairman of Obstetrics and Gynecology branch of Beijing Medical Association and professor of Beijing obstetrics and Gynecology Hospital Affiliated to Capital Medical University, presided over the opening ceremony of the conference. The conference specially set up a special session on stem cells, and invited Professor Wang jianliu, vice president of Peking University People’s Hospital and Professor Liu Baochi of Shanghai public health clinical center as special invited speakers, Professor Liu Baochi’s special lecture entitled “cell therapy for premature ovarian failure” made the participants directly feel the new Gospel of the era brought by cell therapy in the field of Obstetrics and Gynecology, and became a highlight of the conference.
During the meeting, Boyalife held a special meeting on stem cells, and specially invited Professor Wang jianliu, vice president of Peking University People’s Hospital, as the host, and Professor Liu Baochi, Shanghai public health clinical center, as the guest speaker, to give a special speech entitled “cell therapy for premature ovarian failure”.
While introducing the mechanism of mesenchymal stem cells in the treatment of premature ovarian failure, leading medical experts also shared five clinical research projects of mesenchymal stem cells in the treatment of ovarian insufficiency. For example, in 2015, Nanjing Gulou Hospital launched a clinical study on the use of mesenchymal stem cells in the intervention of premature ovarian failure with infertility.
Professor Liu Baochi pointed out in this meeting that among the neonatal perinatal tissues, placental mesenchymal stem cells account for the largest proportion, which can reach 85-90%. There are a large number of cells, which can be used for many times by adults. Moreover, placental derived mesenchymal stem cells have many advantages, such as wide source, no need for matching, convenient collection and so on. At the end of the project, he concluded that the future is the era of cell therapy, and mesenchymal stem cells from perinatal tissue are valuable medical resources.
With the rapid development of stem cell technology, stem cell research and its clinical transformation exploration have rapidly entered the vision of each department of the major third-a hospital. This is especially true in obstetrics and gynecology. From the hospital president to the academic leader of the Department, we attach great importance to the research on the transformation of stem cells and regenerative medicine. In the future, stem cells will bring new hope to the women and obstetrics medical community, and even more patients in medical departments.
Boyalife have been on the way, contributing to the development of stem cell technology. Boyalife owns BioArchive ®、 AXP ® and other many patent stem cell separation and freeze storage platforms, millions of families around the world benefit from Boyalife’s stem cell automation technology. Boyalife are also developing and promoting clinical cooperation with nearly 40 domestic hospitals in the first three, hoping to make the frontier stem cell technology promote change faster and make new technology benefit everyone in need.